Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CEL | P19835 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18067910 | 0.90 | HPGD (0.44) | CYP1A2CELNPC1TP53HPGD | |
| SCHEMBL16901819 | 0.76 | CEL (0.43) | CYP1A2CELHPGDSIGMAR1POLB | |
| SCHEMBL6302944 | 0.75 | S1PR3 (0.43) | CYP1A2CEL | |
| SCHEMBL386099 | 0.74 | S1PR3 (0.45) | CEL | |
| SCHEMBL5169158 | 0.74 | S1PR3 (0.45) | CEL | |
| SCHEMBL385547 | 0.74 | CEL (0.39) | CYP1A2CELSIGMAR1 | |
| SCHEMBL2443148 | 0.74 | CYP1A2 (0.50) | CYP1A2CELNPC1RAB9ASIGMAR1 | |
| SCHEMBL6310394 | 0.73 | CEL (0.38) | CELSIGMAR1 | |
| SCHEMBL386679 | 0.73 | CEL (0.38) | CELSIGMAR1 | |
| SCHEMBL18626660 | 0.72 | CEL (0.41) | CYP1A2CELNPC1TP53HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160263083-A1 | ANTIBACTERIAL AGENTS: ARYL MYXOPYRONIN DERIVATIVES | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2016-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160263083-A1 | ANTIBACTERIAL AGENTS: ARYL MYXOPYRONIN DERIVATIVES | POLRMT, POLR1C, FBL | CYP1A2 737/4885CEL 1062/4885NPC1 3918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.